Can't agree, cohort three is a tiny dose and has three patients. Reporting will be as per what is normal for such trials. No blow by blow account. I see that as prudent.
If , for instance, cohort four provides SVR for all patients then I would expect cohort five to be disregarded and more patients given the cohort four dose. Anything can happen.
